MAPK8 and neoplasm: Treatments of PKR+/+ and PKR−/− tumor cells with SP600125 inhibited JNK1/2 phosphorylation (Supplementary Fig. 4) and increased the proliferation of NEU PKR+/+ cells without eliciting a significant effect on NEU PKR−/− cell proliferation (Fig. 4d).